Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . ESSEX 1ZAT ESSEX BIO - TECHNOLOGY LIMITED 億 勝 生物 科技 有限公司 ( Incorporated in the Cayman Islands with limited liability ) ( Stock Code : 1061 ) INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021 The board ( the “ Board ” ) of directors ( the “ Directors ” ) of Essex Bio - Technology Limited ( the " Company " ) presents the unaudited interim condensed consolidated financial statements of the Company and its subsidiaries ( collectively , the " Group " ) for the six months ended 30 June 2021 together with the comparative figures for the corresponding period in 2020 and the relevant explanatory notes as set out below . FINANCIAL HIGHLIGHTS Presentation Currency in HK $ Comparison Results in RMB For the six months ended 30 June 2020 RMB'000 For the six months ended 30 June 2021 For the six HK $ ' 000 months ended 30 June 2020 HK $ ' 000 Increase For the six months ended 30 June 2021 % RMB'000 Increase % Results Turnover 737,374 323,835 127.7 614,618 293,413 109.5 Profit for the period 162,186 49,188 229.7 135,186 44,567 203.3 Financial ratios Gross profit margin ( Note 1 ) 84.4 % 78.7 % Net profit margin ( Note 2 ) 22.0 % 15.2 % Return on equity ( Note 3 ) 10.3 % 4.2 % Earnings per share - Basic HK28.12 cents HK8.51 cents - Diluted HK27.38 cents HK8.51 cents Dividend per ordinary share – Interim HK4.0 cents EN Nil 1